Krista L Lanctôt

Krista L Lanctôt, PhD

Dr. Krista Lanctôt leads a large interdisciplinary research team whose work has focused on understanding how neuropsychiatric symptoms, such a mild cognitive impairment and mood disorders, interfere with cardiac rehabilitation. The overarching theme of her work is to understand the neurobiologic basis of these symptoms as risk factors for poor response, and use this information to develop targeted interventions. For example, her work has shown links between these symptoms and inflammation, oxidative stress and lipid aberrations. Dr. Lanctôt's team uses a variety of tools including neuroimaging, lipidomics, pharmacogenetics and neuropsychiatric assessments to unravel the link between dysfunction in various cellular and molecular processes and manifestation of these symptoms in a cardiac rehabilitation population. In addition, her group has run clinical trials of dietary, pharmacologic and exercise interventions for these symptoms.

Each year tens of thousands of Canadians are diagnosed with coronary artery disease (CAD) which poses a serious risk to their health and well-being. Depression and associated symptoms of cognitive impairment are common neuropsychiatric symptoms in CAD and have a major negative impact on treatment outcomes and life expectancy. Dr. Lanctôt's work has also shown their negative impact on cardiac rehabilitation outcomes. Understanding the neurobiology of these symptoms may allow us to predict response to cardiac rehabilitation and, on a broader level, may lead to the development of novel therapies.
 
Curr Opin Psychiatry. 2017 Dec 18;:
Sherman C, Ruthirakuhan M, Vieira D, Lanctôt KL, Herrmann N
Cardiovasc Psychiatry Neurol. 2017;2017:3674371
Mazereeuw G, Herrmann N, Andreazza AC, Scola G, Ma DWL, Oh PI, Lanctôt KL
Brain Behav. 2017 Nov;7(11):e00836
Dinoff A, Saleem M, Herrmann N, Mielke MM, Oh PI, Venkata SLV, Haughey NJ, Lanctôt KL
Can J Psychiatry. 2017 Jan 01;:706743717738493
Sun M, Lanctot K, Herrmann N, Gallagher D
J Am Geriatr Soc. 2017 Nov 21;:
Khan MM, Herrmann N, Gallagher D, Gandell D, Fremes SE, Wijeysundera HC, Radhakrishnan S, Sun YR, Lanctôt KL
Expert Rev Respir Med. 2017 Nov 13;:1-16
Wong SK, Li A, Lanctôt KL, Paes B
Alzheimers Dement (N Y). 2017 Sep;3(3):440-449
Lanctôt KL, Amatniek J, Ancoli-Israel S, Arnold SE, Ballard C, Cohen-Mansfield J, Ismail Z, Lyketsos C, Miller DS, Musiek E, Osorio RS, Rosenberg PB, Satlin A, Steffens D, Tariot P, Bain LJ, Carrillo MC, Hendrix JA, Jurgens H, Boot B
Neurodegener Dis Manag. 2017 Oct 18;:
Liu CS, Rau A, Gallagher D, Rajji TK, Lanctôt KL, Herrmann N
Am J Geriatr Psychiatry. 2017 May 15;:
Chee JN, Rapoport MJ, Molnar F, Herrmann N, O'Neill D, Marottoli R, Mitchell S, Tant M, Dow J, Ayotte D, Lanctôt KL, McFadden R, Taylor JP, Donaghy PC, Olsen K, Classen S, Elzohairy Y, Carr DB
J Clin Exp Neuropsychol. 2017 Sep 15;:1-13
Fishman KN, Ashbaugh AR, Lanctôt KL, Cayley ML, Herrmann N, Murray BJ, Sicard M, Lien K, Sahlas DJ, Swartz RH

Pages


Senior Scientist, Evaluative Clinical Sciences, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute
Director, Neuropsychopharmacology Research Program, Sunnybrook Health Science Centre
Professor, Department of Psychiatry, University of Toronto
Professor, Department of Pharmacology and Toxicology, University of Toronto
Full Member, School of Graduate Studies, University of Toronto
Executive Director, MORE research group, Sunnybrook Research Institute